Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Atkins MB, et al. Among authors: bilen ma. J Immunother Cancer. 2023 Mar;11(3):e004780. doi: 10.1136/jitc-2022-004780. J Immunother Cancer. 2023. PMID: 36948504 Free PMC article. Clinical Trial.
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD. Bilen MA, et al. Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17. Cancer. 2019. PMID: 30329148 Free article.
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG. Boilève A, et al. Among authors: bilen ma. J Immunother Cancer. 2018 Dec 27;6(1):159. doi: 10.1186/s40425-018-0482-z. J Immunother Cancer. 2018. PMID: 30591082 Free PMC article.
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Martini DJ, Kline MR, Liu Y, Shabto JM, Williams MA, Khan AI, Lewis C, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA, Bilen MA. Martini DJ, et al. Among authors: bilen ma. Cancer. 2020 Feb 1;126(3):575-582. doi: 10.1002/cncr.32576. Epub 2019 Oct 24. Cancer. 2020. PMID: 31648379 Free article.
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC. Abou Alaiwi S, et al. Among authors: bilen ma. J Immunother Cancer. 2020 Feb;8(1):e000144. doi: 10.1136/jitc-2019-000144. J Immunother Cancer. 2020. PMID: 32066646 Free PMC article.
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA, Lalani AA, Xie W, Steinharter JA, E Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, Choueiri TK. McGregor BA, et al. Among authors: bilen ma. Eur J Cancer. 2020 Aug;135:203-210. doi: 10.1016/j.ejca.2020.05.009. Epub 2020 Jun 27. Eur J Cancer. 2020. PMID: 32599410
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Harvey RD, Carthon BC, Lewis C, Hossain MS, Zhang C, Chen Z, Harris WB, Alese OB, Shaib W, Bilen MA, Lawson DH, Wu C, Steuer CE, El-Rayes BF, Khuri FR, Lonial S, Waller EK, Ramalingam SS, Owonikoko TK. Harvey RD, et al. Among authors: bilen ma. Br J Cancer. 2020 Oct;123(8):1228-1234. doi: 10.1038/s41416-020-0988-2. Epub 2020 Jul 24. Br J Cancer. 2020. PMID: 32704173 Free PMC article. Clinical Trial.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. McGregor BA, et al. Among authors: bilen ma. Cancer. 2021 Mar 15;127(6):840-849. doi: 10.1002/cncr.33328. Epub 2020 Nov 20. Cancer. 2021. PMID: 33216356 Free article. Clinical Trial.
226 results